Cell therapy · developed by Lisata Therapeutics
CLBS201 is a cell therapy made of autologous CD34+ cells, given in a range of 1 x 10^6 to 300 x 10^6 cells. It is being studied in chronic kidney disease, including diabetic nephropathy in patients with type 2 diabetes.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04990427 | Phase 1 | Chronic Kidney Diseases | Completed | LSTA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Chronic Kidney Diseases
Updated Oct 18, 2026. Something wrong or missing? Report it on the LSTA page.
See LSTA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LSTA catalysts and pipeline →